by By Tom Murphy
This Tuesday, Oct. 16, 2012, file photo, shows a portion of The UnitedHealth Group Inc.'s campus in Minnetonka, Minn. The nation's largest health insurer, UnitedHealth, is staking a bigger claim in pharmacy benefits management with a plan to buy Catamaran Corp., for more than $12 billion in cash, the company announced, Monday, March 30, 2015. (AP Photo/Jim Mone, File)
The nation's largest health insurer, UnitedHealth, will muscle up in its fight against rising specialty drug costs by spending more than $12 billion to buy pharmacy benefits manager Catamaran Corp.
Pharmacy benefits managers, or PBMs, help negotiate the prices that customers pay for prescription drugs. They are seen as a key component in the push to contain rising specialty drug costs, an expense that could overwhelm parts of the health care system, especially the federal-state Medicaid program, insurers and other bill payers have warned.
Specialty drugs are complex medicines often represent treatment breakthroughs but come with much higher prices than older drugs. Experts say specialty drugs have always been pricey but confined to relatively small patient populations. That's changing, due in part to some relatively new hepatitis C treatments that could be used by millions of patients.
UnitedHealth and Catamaran said Monday that their deal will combine businesses that have "distinctive, rapidly growing specialty pharmacy services" for a segment of the market that is expected to quadruple from an estimated $100 billion in revenues last year to $400 billion by 2020.
UnitedHealth Group Inc.'s OptumRx PBM business fills about 600 million prescriptions annually. Catamaran expects to fill 400 million this year.
The nation's largest PBM, Express Scripts Holding Co., filled about 1.3 billion prescriptions last year.
Express Scripts executives have spoken out frequently about soaring costs from specialty drugs, and the St. Louis company threw its weight into this fight late last year by restricting coverage. It said in December it will no longer cover Sovaldi and Harvoni—two Gilead Sciences drugs that cost more than $80,000 each for a full course of treatment—or Johnson & Johnson's Olysio except under limited circumstances.
Instead, it made AbbVie Inc.'s Viekira Pak the preferred treatment for its patients.
PBMs can make these restrictions in part because of the leverage they get from the millions of customers they represent. Acquisitions have been a key means of growth in the sector for years.
In 2012, Express Scripts became the nation's largest PBM by completing a $29.1 billion acquisition of rival Medco Health Solutions. That same year, Catamaran changed its name from SXC Health Solutions after spending more than $4 billion to buy another PBM, Catalyst Health.
UnitedHealth said Monday that, for the latest deal, it will spend $61.50 in cash on each share of Catamaran. That's a 27 percent premium to Catamaran's closing price Friday.
Catamaran, based in Schaumburg, Illinois, had about 207.5 million shares outstanding at the end of January, which puts the deal price at roughly $12.76 billion.
The acquisition is expected to close during the fourth quarter.
Shares of Catamaran rose 24 percent, or $11.68, to $60 more than an hour before markets opened Monday. UnitedHealth, based in Minneapolis, also saw its shares climb 3.8 percent, or $4.49, to $122.50.
Explore further: UnitedHealth tops 3Q expectations, raises forecast
© 2015 The Associated Press. All rights reserved.
Medical Xpress on facebook
Related Stories
UnitedHealth tops 3Q expectations, raises forecast
UnitedHealth Group's third-quarter earnings inched up 2 percent but that was enough to help the nation's largest health insurer trump Wall Street expectations and raise its 2014 forecast for the first time ...
Billions can be saved with pharmacy benefit management
(HealthDay)—Efficient pharmacy benefit management, including increasing use of generic drugs and negotiation of market-based pharmacy dispensing fees, could save Medicaid programs billions of dollars nationwide ...
UnitedHealth plans overseas growth with $4.9B deal (Update)
UnitedHealth Group Inc. will spend about $4.9 billion to buy a majority stake in Brazilian health benefits and care provider Amil Participacoes SA, as the largest U.S. health insurer leaps into an international market it ...
Insurers may prove choosy with overhaul exchanges
UnitedHealth CEO Stephen Hemsley is warning analysts not to assume that the insurer will participate widely in a key health care overhaul coverage expansion that unfolds later this year.
AmerisourceBergen expands into animal health with $2.5B deal
Pharmaceutical distributor AmerisourceBergen will stretch its reach into veterinary medicine by spending about $2.5 billion to acquire MWI Veterinary Supply.
Recommended for you
Teva buying Auspex for $3.2 billion
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.
Oral hepatitis B vaccine could become a reality
In a new study, researchers report progress toward perfecting a radical new method of producing vaccines using genetically modified corn. The approach could lead to an oral hepatitis B vaccine that requires no refrigeration ...
Britain to offer all infants meningitis B vaccine
Britain says it will become the first country to offer all babies a vaccine for potentially fatal meningitis B after it reached a price deal with GlaxoSmithKline PLC.
US aims to cut antibiotic use
US President Barack Obama on Friday rolled out plans to cut inappropriate antibiotic use by half, in an effort to tackle drug resistance.
Ebola whole virus vaccine shown effective, safe in primates
An Ebola whole virus vaccine, constructed using a novel experimental platform, has been shown to effectively protect monkeys exposed to the often fatal virus.
FDA to scrutinize unproven alternative remedies (Update)
Federal officials plan to review the safety and evidence behind alternative remedies like Zicam and Cold-Eeze, products that are protected by federal law, but not accepted by mainstream medicine.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
by By Tom Murphy
This Tuesday, Oct. 16, 2012, file photo, shows a portion of The UnitedHealth Group Inc.'s campus in Minnetonka, Minn. The nation's largest health insurer, UnitedHealth, is staking a bigger claim in pharmacy benefits management with a plan to buy Catamaran Corp., for more than $12 billion in cash, the company announced, Monday, March 30, 2015. (AP Photo/Jim Mone, File)
The nation's largest health insurer, UnitedHealth, will muscle up in its fight against rising specialty drug costs by spending more than $12 billion to buy pharmacy benefits manager Catamaran Corp.
Pharmacy benefits managers, or PBMs, help negotiate the prices that customers pay for prescription drugs. They are seen as a key component in the push to contain rising specialty drug costs, an expense that could overwhelm parts of the health care system, especially the federal-state Medicaid program, insurers and other bill payers have warned.
Specialty drugs are complex medicines often represent treatment breakthroughs but come with much higher prices than older drugs. Experts say specialty drugs have always been pricey but confined to relatively small patient populations. That's changing, due in part to some relatively new hepatitis C treatments that could be used by millions of patients.
UnitedHealth and Catamaran said Monday that their deal will combine businesses that have "distinctive, rapidly growing specialty pharmacy services" for a segment of the market that is expected to quadruple from an estimated $100 billion in revenues last year to $400 billion by 2020.
UnitedHealth Group Inc.'s OptumRx PBM business fills about 600 million prescriptions annually. Catamaran expects to fill 400 million this year.
The nation's largest PBM, Express Scripts Holding Co., filled about 1.3 billion prescriptions last year.
Express Scripts executives have spoken out frequently about soaring costs from specialty drugs, and the St. Louis company threw its weight into this fight late last year by restricting coverage. It said in December it will no longer cover Sovaldi and Harvoni—two Gilead Sciences drugs that cost more than $80,000 each for a full course of treatment—or Johnson & Johnson's Olysio except under limited circumstances.
Instead, it made AbbVie Inc.'s Viekira Pak the preferred treatment for its patients.
PBMs can make these restrictions in part because of the leverage they get from the millions of customers they represent. Acquisitions have been a key means of growth in the sector for years.
In 2012, Express Scripts became the nation's largest PBM by completing a $29.1 billion acquisition of rival Medco Health Solutions. That same year, Catamaran changed its name from SXC Health Solutions after spending more than $4 billion to buy another PBM, Catalyst Health.
UnitedHealth said Monday that, for the latest deal, it will spend $61.50 in cash on each share of Catamaran. That's a 27 percent premium to Catamaran's closing price Friday.
Catamaran, based in Schaumburg, Illinois, had about 207.5 million shares outstanding at the end of January, which puts the deal price at roughly $12.76 billion.
The acquisition is expected to close during the fourth quarter.
Shares of Catamaran rose 24 percent, or $11.68, to $60 more than an hour before markets opened Monday. UnitedHealth, based in Minneapolis, also saw its shares climb 3.8 percent, or $4.49, to $122.50.
Explore further: UnitedHealth tops 3Q expectations, raises forecast
© 2015 The Associated Press. All rights reserved.
Medical Xpress on facebook
Related Stories
UnitedHealth tops 3Q expectations, raises forecast
UnitedHealth Group's third-quarter earnings inched up 2 percent but that was enough to help the nation's largest health insurer trump Wall Street expectations and raise its 2014 forecast for the first time ...
Billions can be saved with pharmacy benefit management
(HealthDay)—Efficient pharmacy benefit management, including increasing use of generic drugs and negotiation of market-based pharmacy dispensing fees, could save Medicaid programs billions of dollars nationwide ...
UnitedHealth plans overseas growth with $4.9B deal (Update)
UnitedHealth Group Inc. will spend about $4.9 billion to buy a majority stake in Brazilian health benefits and care provider Amil Participacoes SA, as the largest U.S. health insurer leaps into an international market it ...
Insurers may prove choosy with overhaul exchanges
UnitedHealth CEO Stephen Hemsley is warning analysts not to assume that the insurer will participate widely in a key health care overhaul coverage expansion that unfolds later this year.
AmerisourceBergen expands into animal health with $2.5B deal
Pharmaceutical distributor AmerisourceBergen will stretch its reach into veterinary medicine by spending about $2.5 billion to acquire MWI Veterinary Supply.
Recommended for you
Teva buying Auspex for $3.2 billion
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.
Oral hepatitis B vaccine could become a reality
In a new study, researchers report progress toward perfecting a radical new method of producing vaccines using genetically modified corn. The approach could lead to an oral hepatitis B vaccine that requires no refrigeration ...
Britain to offer all infants meningitis B vaccine
Britain says it will become the first country to offer all babies a vaccine for potentially fatal meningitis B after it reached a price deal with GlaxoSmithKline PLC.
US aims to cut antibiotic use
US President Barack Obama on Friday rolled out plans to cut inappropriate antibiotic use by half, in an effort to tackle drug resistance.
Ebola whole virus vaccine shown effective, safe in primates
An Ebola whole virus vaccine, constructed using a novel experimental platform, has been shown to effectively protect monkeys exposed to the often fatal virus.
FDA to scrutinize unproven alternative remedies (Update)
Federal officials plan to review the safety and evidence behind alternative remedies like Zicam and Cold-Eeze, products that are protected by federal law, but not accepted by mainstream medicine.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment